Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in adult refractory ITP
NCT00706342Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Jan 2007
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fostamatinib in immune thrombocytopenic purpura (ITP), sponsored by Rigel Pharmaceuticals, Inc.. Started Jan 2007; status: completed.
02
Drugs
fostamatinib
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT00706342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00706342.